Welcome to the all-new Vetlearn

  • Vetlearn is getting a new home. Starting this fall,
    Vetlearn becomes part of the NAVC VetFolio family.

    You'll have access to the entire Compendium and
    Veterinary Technician archives and get to explore
    even more ways to learn and earn CE by becoming
    a VetFolio subscriber. Subscriber benefits:
  • Over 500 hours of interactive CE Videos
  • An engaging new Community for tough cases
    and networking
  • Three years of NAVC Conference Proceedings
  • All-new articles (CE and other topics) for the entire
    healthcare team

To access Vetlearn, you must first sign in or register.


  • Registration for new subscribers will open in September 2014!
  • Watch for additional exciting news coming soon!
Become a Member

Reference Desk March 2012

FDA Issues Statement on Compounding of Pergolide Products for Animal Use

    ROCKVILLE, Maryland, March 16, 2012—On September 7, 2011, the U.S. Food and Drug Administration (FDA) approved a new animal drug application (NADA) for a product containing pergolide mesylate (NADA 141-331) marketed under the trade name Prascend Tablets for the control of the clinical signs associated with Cushing’s Disease in horses. Consistent with this approval, the Agency is announcing that it intends to consider the factors set forth in Compliance Policy Guide (CPG) Sec. 608.400 - Compounding of Drugs for Use in Animals (CPG 7125.40) in evaluating potential enforcement actions involving the compounding of pergolide products for animal use from bulk active pharmaceutical ingredient (API).

    In the past, veterinarians prescribed human pergolide products to treat Cushing’s Disease in horses under the “extralabel” use provisions of the Federal Food, Drug, and Cosmetic Act. However, in May 2007, the human pergolide products were removed from the market due to concerns about cardiac side effects in humans. At that time FDA stated that it would work with the sponsors of approved human products and others to ensure that pergolide remained available to treat Cushing’s Syndrome in horses until a new animal drug application was approved for that use. FDA stated that this would include, among other things, exercising enforcement discretion as appropriate over the pharmacy compounding of pergolide for use in animals.

    Consistent with our previous statement, based on the approval of Prascend, FDA intends to apply the Federal Food, Drug, and Cosmetic Act requirements regarding new animal drugs to animal drugs containing pergolide that are compounded from bulk API in accordance with CPG 608.400.

    Source: U.S. Food and Drug Administration


    Did you know... 83% of veterinarians believe that running a veterinary practice is as much a people business as it is a medical service. Read More

    These Care Guides are written to help your clients understand common conditions. They are formatted to print and give to your clients for their information.

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More